43. Zaja F, Baccarani M, Mazza P, et al. Dexamethasone
plus rituximab yields higher sustained response
rates than dexamethasone monotherapy in adults
with primary immune thrombocytopenia. Blood
2010;115:2755–62.
44. Dameshek W, Miller EB. The megakaryocytes in
idiopathic thrombocytopenic purpura, a form of
hypersplenism. Blood 1946;1: 27–50.
45. Kuter DJ. Thrombopoietin and thrombopoietin
mimetics in the treatment of thrombocytopenia.
Annu Rev Med 2009;60:193–206.
46. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a
thrombopoiesis-stimulating protein, for chronic
ITP. N Engl J Med 2006;355:1672–81.
47. Bussel JB, Provan D, Shamsi T, et al. Effect of
eltrombopag on platelet counts and bleeding
during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind,
placebo-controlled trial. Lancet 2009;373:641–8.
48. Bussel JB, Kuter DJ, Pullarkat V, et al. Safety and
efficacy of long-term treatment with romiplostim
in thrombocytopenic patients with chronic ITP.
Blood 2009;113:2161–71.
49. Gernsheimer TB, George JN, Aledort LM, et al.
Evaluation of bleeding and thrombotic events
during long-term use of romiplostim in patients
with chronic immune thrombocytopenia (ITP). J
Thromb Haemost 2010;8:1372–82.
50. Severinsen MT, Engebjerg MC, Farkas DK, et
al. Risk of venous thromboembolism in patients
with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J
Haematol 2011;152:360–2.
51. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag
for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:2237–47.
52. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag
for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3
study. Lancet 2011;377:393–402.
53. Brynes RK, Orazi A, Theodore D, et al. Evaluation
of bone marrow reticulin in patients with chronic
immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study. Am J
Hematol 2015;90:598–601.
54. George JN, Kojouri K, Perdue JJ, Vesely SK.
Management of patients with chronic, refractory idiopathic thrombocytopenic purpura. Semin
Hematol 2000;37:290– 8.
55. McMillan R. Therapy for adults with refractory
chronic immune thrombocytopenic purpura. Ann
Intern Med 1997;126:307–14.
56. Blanco R, Martinez-Taboada VM, Rodriguez-Valverde V, et al. Successful therapy with danazol
in refractory autoimmune thrombocytopenia associated with rheumatic diseases. Br J Rheumatol
1997;36:1095– 9.
57. Provan D, Moss AJ, Newland AC, Bussel JB. Efficacy
of mycophenolate mofetil as single-agent therapy
for refractory immune thrombocytopenic purpura. Am J Hematol 2006;81: 19–25.
58. Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune
thrombocytopenic purpura. Blood 1995;85:351– 8.
59. Figueroa M, Gehlsen J, Hammond D, et al.
Combination chemotherapy in refractory immune
thrombocytopenic purpura. N Engl J Med 1993;
328:1226–9.
60. Newland A, Lee EJ, McDonald V, Bussel JB.
Fostamatinib for persistent/chronic adult immune
thrombocytopenia. Immunotherapy 2 Oct 2017.
61. McCrae KR. Thrombocytopenia in pregnancy.
Hematology Am Soc Hematol Educ Program 2010;
2010:397–402.
62. Gernsheimer T, McCrae KR. Immune thrombocytopenic purpura in pregnancy. Curr Opin
Hematol 2007;14:574–80.
63. DeLoughery TG. Critical care clotting catastroph-ies. Crit Care Clin 2005;21:531–62.
64. Stavrou E, McCrae KR. Immune thrombocytopenia
in pregnancy. Hematol Oncol Clin North Am 2009;
23:1299–316.
65. Sun D, Shehata N, Ye XY, et al. Corticosteroids
compared with intravenous immunoglobulin for
the treatment of immune thrombocytopenia in
pregnancy. Blood 2016;128:1329–35.
66. Kong Z, Qin P, Xiao S, et al. A novel recombinant
human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy.
Blood 2017;130:1097–103.
67. Psaila B, Petrovic A, Page LK, et al. Intracranial
hemorrhage (ICH) in children with immune
thrombocytopenia (ITP): study of 40 cases. Blood
2009;114:4777–83.
68. Journeycake JM. Childhood immune thrombocytopenia: role of rituximab, recombinant thrombopoietin, and other new therapeutics. Hematology
Am Soc Hematol Educ Program 2012;2012:
444– 9.
69. Zhang J, Liang Y, Ai Y, et al. Thrombopoietin-receptor agonists for children with immune
thrombocytopenia: a systematic review. Expert
Opin Pharmacother 2017;18:1543–51.
70. Tarantino MD, Bussel JB, Blanchette VS,
et al. Romiplostim in children with immune
